MannKind | MNKD - Operating Expenses


MannKind reported $119.64M in Operating Expenses for its fiscal quarter ending in December of 2025.





Operating Expenses Change Date
Adma Biologics USD 83.21M 4.02M Sep/2025
BioCryst Pharmaceuticals USD 146.17M 534.06M Dec/2025
Eli Lilly USD 10.31B 1.09B Dec/2025
Halozyme Therapeutics USD 211.07M 74.73M Dec/2025
Insmed USD 513.55M 109.86M Dec/2025
Karyopharm Therapeutics USD 61.82M 3.24M Dec/2024
MacroGenics USD 67M 8M Sep/2025
MannKind USD 119.64M 56.29M Dec/2025
Merck USD 10.16B 558M Dec/2025
Minerva Neurosciences USD 4.52M 155.46K Dec/2024
Novavax USD 126.2M 23.62M Dec/2025
Novo Nordisk DKK 6.5B 32.8B Jun/2025
Pfizer USD 12.91B 79.89B Dec/2025
Sanofi EUR 10.51B 1.21B Dec/2025
Xencor USD 81.86M 13.35M Dec/2025